Plasma Proteomic Profiling of Comorbid and Noncomorbid COVID-19 Patients in ICU
Journal of Proteome Research · 2026
DOI: 10.1021/acs.jproteome.6c00467 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Proteome Research, 2026. Verfasst von Sara Taleb und 6 weiteren Autor:innen. Beteiligte Einrichtung: Proteomics Core, Research, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, PO 24144, Doha, Qatar. Hauptthemen laut MEDLINE: COVID-19, Proteomics, Diabetes Mellitus, Type 2, Hypertension. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Hamad Medical Corporation, Weill Cornell Medicine - Qatar.
Abstract (Originalsprache)
Type 2 Diabetes (T2D) and hypertension (HTN) are common comorbidities in severe COVID-19, yet their specific impact on proteomic recovery remains unclear. This study analyzed plasma protein signatures of critical COVID-19 patients with and without these comorbidities (COVID-only group [COG] and COVID comorbid group [CTHG]) on the first and last days of ICU stay. Proteomic analysis revealed a systemic shift characterized by upregulated immune responses and downregulated metabolic processes at admission across all patients. Survival was fundamentally defined by the restoration of homeostasis; liver-derived proteins─including LPA, TTR, and AHSG─were initially suppressed but rebounded significantly in survivors. This homeostatic recovery was impaired in CTHG compared to COG, with CTHG survivors showing attenuated recovery of metabolic markers. Distinct mortality-associated signatures also emerged between groups. COG nonsurvivors exhibited liver failure and severe hemolysis marked by persistent suppression of haptoglobin (HP). In contrast, CTHG mortality was driven by lipid metabolism dysregulation, with CD5L and APOA2 levels dropping specifically in comorbid nonsurvivors, often accompanied by a paradoxical elevation in APOA4─likely reflecting impaired renal clearance rather than restored lipid homeostasis. These findings indicate that preexisting T2D and HTN hinder physiological resolution of metabolic and lipid dysregulation, providing proteomic evidence for distinct mortality risks associated with failure to restore metabolic homeostasis in comorbid COVID-19 patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Proteomics Core, Research, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, PO 24144, Doha, Qatar.
- Bioinformatics Core, Research, Weill Cornell Medicine-Qatar, Education City, Qatar Foundation, PO 24144, Doha, Qatar.
- Medical Intensive Care Unit, Hamad Medical Corporation, Doha, Qatar.
ORCID-Profile: Nisha Stephan, Praveen Babu Vemulapalli, Karsen Suhre, Sunkyu Choi
Förderung
- Hamad Medical Corporation
- Weill Cornell Medicine - Qatar
Zitieren
APA
Taleb, S., Stephan, N., Vemulapalli, P. B., Suhre, K., Hssain, A. A., Schmidt, F., & Choi, S. (2026). Plasma Proteomic Profiling of Comorbid and Noncomorbid COVID-19 Patients in ICU. Journal of Proteome Research. https://doi.org/10.1021/acs.jproteome.6c00467
Vancouver
Taleb S, Stephan N, Vemulapalli PB, Suhre K, Hssain AA, Schmidt F, et al. Plasma Proteomic Profiling of Comorbid and Noncomorbid COVID-19 Patients in ICU. Journal of Proteome Research. 2026. doi:10.1021/acs.jproteome.6c00467
BibTeX
@article{Taleb2026,
author = {Taleb, Sara and Stephan, Nisha and Vemulapalli, Praveen Babu and Suhre, Karsen and Hssain, Ali Ait and Schmidt, Frank and Choi, Sunkyu},
title = {Plasma Proteomic Profiling of Comorbid and Noncomorbid COVID-19 Patients in ICU},
journal = {Journal of Proteome Research},
year = {2026},
doi = {10.1021/acs.jproteome.6c00467}
}
EUVIMED